BioWorld

Nov. 20, 2007

Celgene's $2.9B For Pharmion Nets Hematology, Cancer Lines

Celgene Corp. is acquiring Pharmion Corp. for $2.9 billion in a cash and stock deal that will expand the Summit, N.J.-based biotech's presence in the global hematology and oncology markets. (BioWorld Today) Read More

No Surprise As Onyx's Nexavar Wins Approval In Liver Cancer

Speedel, Novartis In Dispute On Flow Of Aliskiren Data

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...